What is Euglycemic Diabetic Ketoacidosis (Euglycemic DKA)?
Euglycemic DKA is a life-threatening variant of diabetic ketoacidosis characterized by metabolic acidosis, ketonemia, and blood glucose levels below 250 mg/dL—critically, the absence of marked hyperglycemia makes this diagnosis easily missed and delays treatment. 1, 2, 3
Key Diagnostic Features
Euglycemic DKA presents with the same metabolic derangements as classic DKA but with unexpectedly low glucose levels (typically <250 mg/dL, sometimes even normal). The diagnostic triad includes:
- Metabolic acidosis: pH <7.3, bicarbonate <15-18 mEq/L
- Ketonemia/ketonuria: Elevated β-hydroxybutyrate (preferred test) or positive ketones
- Blood glucose <250 mg/dL (often 100-200 mg/dL range) 4, 5, 6
The anion gap is elevated (>10-12), confirming high anion gap metabolic acidosis 7.
Primary Causes and Risk Factors
SGLT-2 Inhibitors (Most Common Modern Cause)
The widespread use of SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) has dramatically increased euglycemic DKA incidence 4, 8, 5. These medications:
- Cause urinary glucose loss, preventing hyperglycemia
- Create a baseline state of mild ketonemia
- Lower the threshold for ketoacidosis development
- Can trigger euglycemic DKA within 48-72 hours of initiation or after prolonged use 9, 10
Other Precipitating Factors
- Ketogenic/low-carbohydrate diets: Severe carbohydrate restriction combined with insulin deficiency 11, 9
- Pregnancy: Particularly in gestational or pre-existing diabetes 6, 12
- Starvation/reduced oral intake: Any cause of prolonged fasting 6
- Acute illness/infection: Sepsis, influenza, surgical stress 8, 9, 13
- Insulin pump failure 6
- Bariatric surgery, gastroparesis, chronic liver disease 6
Pathophysiology
The mechanism involves:
- Relative insulin deficiency (milder than classic DKA) coupled with elevated counterregulatory hormones
- Carbohydrate deficit (from SGLT-2 inhibitor glycosuria, dietary restriction, or reduced intake)
- Increased glucagon/insulin ratio driving lipolysis and ketogenesis
- Prevention of hyperglycemia by ongoing glucose loss (SGLT-2 inhibitors) or lack of substrate 4, 6
Clinical Presentation
Symptoms (Non-specific and Easily Missed)
- Nausea, vomiting, abdominal pain
- Malaise, fatigue, weakness
- Polyuria (may be present)
- Kussmaul respirations (deep, labored breathing from acidosis)
- Altered mental status (less common than in hyperglycemic DKA) 7, 12
Critical Diagnostic Pitfall
The normal or mildly elevated glucose misleads clinicians into dismissing DKA, causing dangerous delays. Always check blood ketones (β-hydroxybutyrate preferred) and arterial/venous blood gas in any diabetic patient with unexplained metabolic symptoms, regardless of glucose level 5, 6, 12.
Why This Matters for Morbidity and Mortality
Delayed diagnosis leads to:
- Prolonged severe acidosis (pH <7.0 possible)
- Electrolyte derangements (hypokalemia, hypophosphatemia)
- Cardiac arrhythmias and respiratory depression
- Cerebral edema risk (though less than hyperglycemic DKA)
- Higher mortality if untreated 6
The half-life of SGLT-2 inhibitors (12-24 hours) means euglycemic DKA may be more prolonged than classic DKA, requiring extended treatment 4.
Treatment Approach (Modified from Classic DKA)
Immediate Management
- Start dextrose-containing IV fluids immediately (5-10% dextrose in normal saline)—this is the key difference from hyperglycemic DKA management 4, 11, 6
- Delay insulin infusion until glucose rises above 250 mg/dL if patient presents with glucose <200 mg/dL 11
- If glucose >200 mg/dL: Begin standard insulin infusion (0.1 units/kg/hour) with dextrose-containing fluids 1
Rationale for Dextrose
- Provides substrate to suppress ketogenesis
- Stimulates endogenous insulin secretion
- Prevents hypoglycemia during insulin therapy
- Corrects the carbohydrate deficit driving ketosis 4, 6
Monitoring
- β-hydroxybutyrate levels (not urine ketones—nitroprusside method misses β-hydroxybutyrate and shows false worsening as it converts to acetoacetate) 14, 7
- Anion gap and venous pH every 2-4 hours
- Electrolytes (especially potassium, phosphate)
- Blood glucose every 1-2 hours 5
Resolution Criteria
- Anion gap normalized (<12)
- pH >7.3
- Bicarbonate ≥18 mEq/L
- Ketones cleared (β-hydroxybutyrate <0.6 mmol/L) 14, 5
Transition to Subcutaneous Insulin
Slower transition than classic DKA—continue IV insulin 2-4 hours after subcutaneous basal insulin given to prevent rebound ketoacidosis 1, 2, 5. The prolonged SGLT-2 inhibitor effect necessitates this caution.
Prevention Strategies
For Patients on SGLT-2 Inhibitors
- Discontinue SGLT-2 inhibitors 3-4 days before surgery 1
- Sick-day rules: Stop SGLT-2 inhibitor during acute illness, fasting, or reduced oral intake 8, 9
- Avoid ketogenic diets while on SGLT-2 inhibitors 11, 9
- Early follow-up after initiation (within 1-2 weeks) for treatment-naive patients 10
High-Risk Situations Requiring SGLT-2 Inhibitor Cessation
- Major surgery or procedures
- Acute infection/sepsis
- Prolonged fasting (>12-24 hours)
- Gastrointestinal illness with vomiting/diarrhea
- Pregnancy 8, 9, 13
Key Clinical Pearls
- Think euglycemic DKA in any diabetic patient with metabolic acidosis and elevated anion gap, regardless of glucose level
- SGLT-2 inhibitor use is the most important historical clue in modern practice 5, 12
- Blood ketone testing (β-hydroxybutyrate) is essential—urine ketones alone are inadequate 14, 12
- Dextrose-containing fluids are mandatory from the start—this is non-negotiable and distinguishes treatment from classic DKA 4, 11, 6
- Insulin requirements are often surprisingly low compared to hyperglycemic DKA 9, 10
- Consider reassessing diabetes phenotype when insulin needs are minimal despite severe ketoacidosis—may indicate preserved beta-cell function 9